Observational studyJournal of gastrointestinal cancer2025
Area Deprivation Index as a Predictor of Hepatocellular Carcinoma Prognosis: Limited Predictive Utility in an Integrated Care Model.
Observational study in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, yet mortality outcomes in patients with HCC can vary widely. Socioeconomic disparities are known to influence health outcomes in patients with various cancers. We aim to investigate the relationship between socioeconomic status as measured by the Area Deprivation Index (ADI) and risk of mortality and Barcelona Clinic Liver Cancer (BCLC) stage at the time of diagnosis in patients with HCC.
methodsA retrospective cross-sectional study of patients treated for HCC at an academic liver center between January 1, 2016, and December 31, 2020. The primary outcome was time to cause-specific death. The secondary outcome was BCLC stage at the time of HCC diagnosis.
resultsA total of 980 patients (median age 66 years; interquartile range 61-72) were included. ADI was not a significant predictor of mortality across all ADI quintiles. Severity of HCC at diagnosis was associated with increasing deprivation at the state level ADI (P < 0.5 at all quintiles) but not the national ADI level. Advanced BCLC stage (C and D) was significantly associated with cause-specific death in patients with HCC in both models (hazard ratio, 1.94, 95% CI, 1.44-2.62; P < 0.001; hazard ratio, 1.94; 95% CI, 1.44-2.61; P < 0.001).
conclusionIn patients with HCC treated at an academic liver center, ADI was associated with the severity of cancer at HCC diagnosis; however, mortality risk remained consistent across all ADI quintiles. Access to centers that provide coordinated, multidisciplinary HCC care may help mitigate the impact of socioeconomic disparities on HCC mortality.
Indexed as
Identifiers
41091234What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.